Close
Help




JOURNAL

Clinical Medicine Reviews in Therapeutics

Golimumab-A Review of its Therapeutic Efficacy in Rheumatoid Arthritis

Submit a Paper


Clinical Medicine Reviews in Therapeutics 2010:2

Review

Published on 12 Jul 2010

DOI: 10.4137/CMRT.S4775


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics

Abstract

The advent of monoclonal antibodies to Tumor necrosis factor-α (TNF), has revolutionized the treatment in rheumatoid arthritis (RA). These agents have proved to be highly efficacious, making remission an achievable goal in RA. Golimumab is a human monoclonal antibody to TNF, which is approved by the US FDA for the treatment of RA, psoriatic arthritis and ankylosing spondylitis since April 2009. Golimumab is a useful addition to the therapeutic armamentarium against rheumatoid arthritis. It has proven efficacy in RA patients with active disease, despite treatment with methotrexate and also found to be useful in patients who have failed on a prior anti-TNF agent. It offers a reasonable alternative to other anti-TNF drugs like infliximab, adalimumab or etanercept. The short-term safety profile, based on short-term RCTs, is reasonable with no differences in total adverse events, serious infections, cancer, tuberculosis or deaths. However, Long-term surveillance studies are needed for safety assessment.



Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




What Your Colleagues Say About Libertas Academica
It is an honor to publish in Libertas Academia journals, I strongly recommend researchers to submit their articles.  The entire submission, review and publication process for our article in Retrovirology: Research and Treatment was clear and easy.  The staff explained everything and helped me whenever I asked, they were supportive and very polite.  Comments from reviewers were professional and very helpful in improving the quality of the manuscript. Publication fees were reasonable and fair.  As ...
Dr Mqondisi Tshabalala (University of Zimbabwe, Avondale Harare, Zimbabwe)
More Testimonials

Quick Links


New article and journal news notification services